DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Response of Topical Capsaicin in Alopecia Areata

Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alopecia Areata

Intervention: Capsaicin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of Minnesota - Clinical and Translational Science Institute

Official(s) and/or principal investigator(s):
Maria Hordinsky, MD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute
Marna Ericson, Ph D, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute

Summary

It has been postulated that Alopecia Areata (AA) is, at least in part, a neurologically mediated disease. Research supporting this theory includes the finding that nerves surrounding the hair follicles are collapsed. We want to take this research a step further and show that not only are these perifollicular nerves collapsed, but that their function is also impaired.

Clinical Details

Official title: Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Topical capsaicin will quantitatively decrease the amount of Substance P in the scalp of AA patients.

Secondary outcome: The scalps of AA patients may be less sensitive to stimuli.

Detailed description: To assess the function of perifollicular scalp nerves in AA we will look at the response of these nerves to the topical medication capsaicin. Under normal circumstances topical capsaicin is known to target nerves in the peripheral nervous system causing short-term release of the neuropeptide Substance P (SP) as well as long-term transient depletion of SP. We expect the AA patients will respond abnormally to topical capsaicin treatment.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Must have alopecia totalis or universalis.

- Be in good health.

- Not be taking any medications including topical medications

- Be 18 years or older.

- Be willing to apply study medication or vehicle as directed, comply with instructions

and commit to follow-up visits.

- Not have had hair chemically treated (including colored hair, permed hair, etc)

within the month prior to the study. Exclusion Criteria:

- Absence of extensive alopecia areata.

- People not in good health.

- People taking medications.

- Allergies to capsaicin.

- Presence of irritated or visibly inflamed scalp.

- Having had hair chemically treated (including colored hair, permed hair, etc.) within

the month prior to study.

Locations and Contacts

University of Minnesota, Minneapolis, Minnesota 55455, United States
Additional Information

Starting date: August 1997
Last updated: May 30, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017